RICHARD GAYNOR Insider Trading $NTGN Neon Therapeutics, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for RICHARD GAYNOR.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of RICHARD GAYNOR. RICHARD GAYNOR is Director in INFINITY PHARMACEUTICALS, INC. ($INFI) and Director in Alkermes plc. ($ALKS) and President of R&D in Neon Therapeutics, Inc. ($NTGN).
RICHARD GAYNOR in Neon Therapeutics, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of RICHARD GAYNOR: President of R&D
Holdings: 0 shares
Latest Transaction: May 06 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of RICHARD GAYNOR in Neon Therapeutics, Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALKS, INFI, NTGN
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 06 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Option Exercise | D | 2.65 | 155,373 | 411,738 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Option Exercise | D | 6.13 | 105,000 | 643,650 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Option Exercise | D | 10.20 | 58,005 | 591,651 | 0 | |
| May 06 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Sell | D | 0.00 | 210,410 | 0 | 0 | 210.4 K to 0 (-100.00 %) |
| Mar 02 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Payment of Exercise | F | 1.50 | 5,625 | 8,438 | 210,410 | 216 K to 210.4 K (-2.60 %) |
| Feb 27 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Payment of Exercise | F | 1.51 | 5,465 | 8,252 | 216,035 | 221.5 K to 216 K (-2.47 %) |
| Jan 13 2020 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Grant | A | 0.00 | 65,000 | 0 | 221,500 | 156.5 K to 221.5 K (+41.53 %) |
| Nov 27 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Sell | S | 1.24 | 22,322 | 27,644 | 156,500 | 178.8 K to 156.5 K (-12.48 %) |
| Nov 27 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Sell | S | 1.31 | 23,000 | 30,231 | 178,822 | 201.8 K to 178.8 K (-11.40 %) |
| Nov 27 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Sell | S | 1.37 | 20,000 | 27,498 | 201,822 | 221.8 K to 201.8 K (-9.02 %) |
| Nov 25 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Grant | A | 0.00 | 75,000 | 0 | 221,822 | 146.8 K to 221.8 K (+51.08 %) |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Option Exercise | A | 6.13 | 105,000 | 643,650 | 105,000 | |
| Mar 01 2019 | NTGN | Neon Therapeutics, ... | GAYNOR RICHARD | President of R&D | Grant | A | 0.00 | 57,500 | 0 | 146,822 | 89.3 K to 146.8 K (+64.37 %) |
Page: 1